The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of
adult CNS cancers ranging from noninvasive and surgically curable pilocytic astrocytomas …

Resistance to anticancer therapies includes primary resistance, usually related to lack of
target dependency or presence of additional targets, and secondary resistance, mostly …

PURPOSE Approximately 10% of patients with epidermal growth factor receptor (EGFR)
mutation–positive non–small-cell lung cancer (NSCLC) harbor uncommon mutations. Here …

Neoantigens are considered to be ultimate target of tumor immunotherapy due to their high
tumor specificity and immunogenicity. Dendritic cell (DCs) vaccines based on neoantigens …

Purpose ARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus
gefitinib in treatment-naıve patients with advanced non–small-cell lung cancer (NSCLC) and …

We report a phase II study of 50 advanced non-small cell lung cancer (NSCLC) patients with
point mutations or insertions in EGFR exon 20 treated with poziotinib (NCT03066206). The …

The advent of precision medicine has brought light to the treatment of non-small cell lung
cancer (NSCLC), expanding the options for patients with advanced NSCLC by targeting …

PURPOSE Standard first-line therapy for EGFR-mutant advanced non–small-cell lung
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …

Purpose In patients with epidermal growth factor receptor (EGFR) mutation–positive
advanced non–small-cell lung cancer (NSCLC), there is an unmet need for EGFR–tyrosine …

Background We evaluated the efficacy and safety of tepotinib, a potent and highly selective
oral MET inhibitor, plus gefitinib in patients with epidermal growth factor receptor (EGFR) …